← Browse by Condition
Medical Condition
metastatic gastroesophageal junction adenocarcinoma
Total Trials
3
Recruiting Now
3
Trial Phases
Phase 1, Phase 2, Phase 1, Phase 2, Phase 3
NCT06329973 Phase 1, Phase 2
Recruiting
Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer
Enrollment
70 pts
Location
China
Sponsor
Henan Cancer Hospital
NCT04704661 Phase 1
Recruiting
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Enrollment
51 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
NCT06203600 Phase 2, Phase 3
Recruiting
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
Enrollment
224 pts
Location
United States
Sponsor
National Cancer Institute (NCI...